Arterial stiffness as a therapeutic target for isolated systolic hypertension: Focus on vascular calcification and fibrosis

Current Hypertension Reviews

Volumn 6, Issue 1, 2010, Pages 20-31

  Bouvet, Céline ^a   Essalihi, Rachida ^a   Gilbert, Liz Ann ^a   Moreau, Simon ^a   Moreau, Pierre ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Arterial stiffness; Elastocalcinosis; Endothelin; Matrix metalloproteinases; Nitric oxide; Transforming growth factor; Vascular fibrosis

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATENOLOL; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXYCYCLINE; ELASTIN; HYDROCHLOROTHIAZIDE; IRBESARTAN; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; N(G) METHYLARGININE; NEBIVOLOL;

ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; BLOOD VESSEL CALCIFICATION; CALCINOSIS; ELASTOCALCINOSIS; ESSENTIAL HYPERTENSION; EXPERIMENTAL MODEL; EXTRACELLULAR MATRIX; HEART VENTRICLE EJECTION; HUMAN; HYPERTENSION; ISOLATED SYSTOLIC HYPERTENSION; NONHUMAN; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; VASCULAR FIBROSIS; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE;

EID: 77949709368     PISSN: 15734021     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340210790231726     Document Type: Review

References (146)

1. Kannel WB. Prevalence and implications of uncontrolled systolic hypertension. Drugs Aging 2003; 20: 277-86.
2. Darne B, Girerd X, Safar M, Cambien F, Guize L. Pulsatile versus steady component of blood pressure: a cross-sectional analysis and a prospective analysis on cardiovascular mortality. Hypertension 1989; 13: 392-400.
3. Franklin SS. Is there a preferred antihypertensive therapy for isolated systolic hypertension and reduced arterial compliance? Curr Hypertens Rep 2000; 2: 253-9.
4. Thijs L, Den Hond E, Nawrot T, Staessen JA. Prevalence, pathophysiology and treatment of isolated systolic hypertension in the elderly. Expert Rev Cardiovasc Ther 2004; 2: 761-9.
5. Safar ME, Blacher J, Pannier B, et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39: 735-8.
6. Benetos A, Rudnichi A, Safar M, Guize L. Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertension 1998; 32: 560-4.
7. O'Rourke MF. Isolated systolic hypertension, pulse pressure, and arterial stiffness as risk factors for cardiovascular disease. Curr Hypertens Rep 1999; 1: 04-11.
8. Blacher J, Staessen JA, Girerd X, et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000; 160:1085-9.
9. Glynn RJ, L'Italien GJ, Sesso HD, Jackson EA, Buring JE. Development of predictive models for long-term cardiovascular risk associated with systolic and diastolic blood pressure. Hypertension 2002; 39:105-10.
10. Dyer AR, Stamler J, Shekelle RB, et al. Pulse pressure-III. Prognostic significance in four Chicago epidemiologic studies. J Chronic Dis 1982; 35: 283-94.
11. Glynn RJ, Chae CU, Guralnik JM, Taylor JO, Hennekens CH. Pulse pressure and mortality in older people. Arch Intern Med 2000; 160: 2765-72.
12. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. Circulation 1999; 100: 354-60.
13. Gasowski J, Fagard RH, Staessen JA, et al. Pulsatile blood pressure component as predictor of mortality in hypertension: a metaanalysis of clinical trial control groups. J Hypertens 2002; 20:145-51.
14. Benetos A, Laurent S, Hoeks AP, Boutouyrie PH, Safar ME. Arterial alterations with aging and high blood pressure. A noninvasive study of carotid and femoral arteries. Arterioscler Thromb 1993; 13: 90-7.
15. Nejjar I, Pieraggi MT, Thiers JC, Bouissou H. Age-related changes in the elastic tissue of the human thoracic aorta. Atherosclerosis 1990; 80:199-208.
16. Long DA, Newaz MA, Prabhakar SS, et al. Loss of nitric oxide and endothelial-derived hyperpolarizing factor-mediated responses in aging. Kidney Int 2005; 68: 2154-63.
17. McEniery CM, Qasem A, Schmitt M, Avolio AP, Cockcroft JR, Wilkinson IB. Endothelin-1 regulates arterial pulse wave velocity in vivo. J Am Coll Cardiol 2003; 42:1975-81.
18. McEniery CM, Yasmin, Wallace S, et al. Increased stroke volume and aortic stiffness contribute to isolated systolic hypertension in young adults. Hypertension 2005; 46:221-6.
19. London GM, Marchais SJ, Guerin AP, Pannier B. Arterial stiffness: pathophysiology and clinical impact. Clin Exp Hypertens 2004; 26: 689-99.
20. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236-41.
21. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338:1281-5.
22. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757-64.
23. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755-62.
24. Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Roccella EJ, Levy D. Differential control of systolic and diastolic blood pressure : factors associated with lack of blood pressure control in the community. Hypertension 2000; 36: 594-9.
25. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15:1014-21.
26. Blumenthal H, Lansing A, Wheeler P. Calcification of the media of the human aorta and its relation to intimal arteriosclerosis, ageing and disease. Am J Pathol 1944; 20: 665-679.
27. Atkinson J. Arterial calcification. Mechanisms, consequences and animal models. Pathol Biol (Paris) 1999; 47: 677-84.
28. Elliott RJ, McGrath LT. Calcification of the human thoracic aorta during aging. Calcif Tissue Int 1994; 54: 268-73.
29. Bailey M, Pillarisetti S, Jones P, Xiao H, Simionescu D, Vyavahare N. Involvement of matrix metalloproteinases and tenascin-C in elastin calcification. Cardiovasc Pathol 2004; 13:146-55.
30. Atkinson J. Aging of arterial extracellular matrix elastin: etiology and consequences. Pathol Biol (Paris) 1998; 46: 555-9.
31. Niederhoffer N, Lartaud-Idjouadiene I, Giummelly P, Duvivier C, Peslin R, Atkinson J. Calcification of medial elastic fibers and aortic elasticity. Hypertension 1997; 29: 999-1006.
32. Essalihi R, Dao HH, Yamaguchi N, Moreau P. A new model of isolated systolic hypertension induced by chronic warfarin and vitamin K1 treatment. Am J Hypertens 2003; 16:103-10.
33. McEniery CM, McDonnell BJ, So A, et al. Aortic calcification is associated with aortic stiffness and isolated systolic hypertension in healthy individuals. Hypertension 2009; 53: 524-31.
34. Gaillard V, Casellas D, Seguin-Devaux C, et al. Pioglitazone improves aortic wall elasticity in a rat model of elastocalcinotic arteriosclerosis. Hypertension 2005; 46: 372-9.
35. Bouvet C, Moreau S, Blanchette J, de Blois D, Moreau P. Sequential activation of matrix metalloproteinase 9 and transforming growth factor beta in arterial elastocalcinosis. Arterioscler Thromb Vasc Biol 2008; 28: 856-62.
36. Hornebeck W, Derouette JC, Roland J, Chatelet F, Bouissou H, Robert L. Correlation between age, arteriosclerosis and elastinolytic activity of human aorta wall. C R Acad Sci Hebd Seances Acad Sci D 1976; 282: 2003-6.
37. Chapman HA, Riese RJ, Shi GP. Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 1997; 59: 63-88.
38. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998; 102: 576-83.
39. Zhu L, Wigle D, Hinek A, et al. The endogenous vascular elastase that governs development and progression of monocrotalineinduced pulmonary hypertension in rats is a novel enzyme related to the serine proteinase adipsin. J Clin Invest 1994; 94:1163-71.
40. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001; 21:1104-17.
41. Stocker W, Grams F, Baumann U, et al. The metzincins - topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci 1995; 4: 823-40.
42. Liu PY, Tsai WC, Lin CC, Hsu CH, Haung YY, Chen JH. Invasive measurements of pulse wave velocity correlate with the degree of aortic valve calcification and severity associated with matrix metalloproteinases in elderly patients with aortic valve stenosis. Clin Sci (Lond) 2004; 107: 415-22.
43. Medley TL, Kingwell BA, Gatzka CD, Pillay P, Cole TJ. Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ Res 2003; 92:1254-61.
44. Medley TL, Cole TJ, Dart AM, Gatzka CD, Kingwell BA. Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler Thromb Vasc Biol 2004; 24:1479-84.
45. Yasmin, McEniery CM, Wallace S, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25: 372.
46. Toda T, Tsuda N, Nishimori I, Leszczynski DE, Kummerow FA. Morphometrical analysis of the aging process in human arteries and aorta. Acta Anat (Basel) 1980; 106: 35-44.
47. Keeley FW, Partridge SM. Amino acid composition and calcification of human aortic elastin. Atherosclerosis 1974; 19: 287-96.
48. Vyavahare N, Jones PL, Tallapragada S, Levy RJ. Inhibition of matrix metalloproteinase activity attenuates tenascin-C production and calcification of implanted purified elastin in rats. Am J Pathol 2000; 157: 885-93.
49. Basalyga DM, Simionescu DT, Xiong W, Baxter BT, Starcher BC, Vyavahare NR. Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation 2004; 110: 3480-7.
50. Qin X, Corriere MA, Matrisian LM, Guzman RJ. Matrix metalloproteinase inhibition attenuates aortic calcification. Arterioscler Thromb Vasc Biol 2006; 26:1510-6.
51. Labat-Robert J. Cell-matrix interactions in aging: role of receptors and matricryptins. Ageing Res Rev 2004; 3: 233-47.
52. Hindson VJ, Ashworth JL, Rock MJ, Cunliffe S, Shuttleworth CA, Kielty CM. Fibrillin degradation by matrix metalloproteinases: identification of amino- and carboxy-terminal cleavage sites. FEBS Lett 1999; 452:195-8.
53. Sinha S, Heagerty AM, Shuttleworth CA, Kielty CM. Expression of latent TGF-beta binding proteins and association with TGF-beta 1 and fibrillin-1 following arterial injury. Cardiovasc Res 2002; 53: 971-83.
54. Simionescu A, Philips K, Vyavahare N. Elastin-derived peptides and TGF-beta1 induce osteogenic responses in smooth muscle cells. Biochem Biophys Res Commun 2005; 334: 524-32.
55. Watson KE, Bostrom K, Ravindranath R, Lam T, Norton B, Demer LL. TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblastlike vascular cells to calcify. J Clin Invest 1994; 93: 2106-13.
56. Lee JS, Basalyga DM, Simionescu A, Isenburg JC, Simionescu DT, Vyavahare NR. Elastin calcification in the rat subdermal model is accompanied by up-regulation of degradative and osteogenic cellular responses. Am J Pathol 2006; 168: 490-8.
57. Parhami F, Tintut Y, Patel JK, Mody N, Hemmat A, Demer LL. Regulation of vascular calcification in atherosclerosis. Z Kardiol 2001; 90 (Suppl 3): 27-30.
58. Shanahan CM, Proudfoot D, Tyson KL, Cary NR, Edmonds M, Weissberg PL. Expression of mineralisation-regulating proteins in association with human vascular calcification. Z Kardiol 2000; 89 (Suppl 2): 63-8.
59. Wallin R, Wajih N, Greenwood GT, Sane DC. Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. Med Res Rev 2001; 21: 274-301.
60. Steitz SA, Speer MY, Curinga G, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001; 89:1147-54.
61. Essalihi R, Ouellette V, Hao Dao H, McKee MD, Moreau P. Phenotypic modulation of vascular smooth muscle cells during medial arterial calcification: a Role for Endothelin? J Cardiovasc Pharmacol 2004; 44: S147-S150.
62. Ahmed S, O'Neill KD, Hood AF, Evan AP, Moe SM. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis 2001; 37:1267-76.
63. Shanahan CM, Cary NR, Salisbury JR, Proudfoot D, Weissberg PL, Edmonds ME. Medial localization of mineralization-regulating proteins in association with Monckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation 1999; 100: 2168-76.
64. Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: E10-7.
65. Giachelli CM, Jono S, Shioi A, Nishizawa Y, Mori K, Morii H. Vascular calcification and inorganic phosphate. Am J Kidney Dis 2001; 38: S34-7.
66. Zhang J, Fu M, Myles D, et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett 2002; 521:180-4.
67. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993; 91:1800-9.
68. Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res 2006; 99: 1044-59.
69. Zebboudj AF, Shin V, Bostrom K. Matrix GLA protein and BMP-2 regulate osteoinduction in calcifying vascular cells. J Cell Biochem 2003; 90: 756-65.
70. th ed. London: Arnold, 2003; p. 372.
71. Delanian S, Porcher R, Balla-Mekias S, Lefaix JL. Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol 2003; 21: 2545-50.
72. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 105: 2512-7.
73. Safar ME. Hypothesis on isolated systolic hypertension in the elderly. J Hum Hypertens 1999; 13: 813-5.
74. Hsu HH, Tawfik O, Sun F. Mechanism of dystrophic calcification in rabbit aortas: temporal and spatial distributions of calcifying vesicles and calcification-related structural proteins. Cardiovasc Pathol 2004; 13: 3-10.
75. Watson KE, Parhami F, Shin V, Demer LL. Fibronectin and collagen I matrixes promote calcification of vascular cells in vitro, whereas collagen IV matrix is inhibitory. Arterioscler Thromb Vasc Biol 1998; 18:1964-71.
76. Merx MW, Schafer C, Westenfeld R, et al. Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-A-deficient mice. J Am Soc Nephrol 2005; 16: 3357-64.
77. Nakaoka T, Gonda K, Ogita T, et al. Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2. J Clin Invest 1997; 100: 2824-32.
78. Taylor LM, Khachigian LM. Induction of platelet-derived growth factor B-chain expression by transforming growth factor-beta involves transactivation by Smads. J Biol Chem 2000; 275:16709-16.
79. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008; 22:1276-312.
80. Igarashi A, Okochi H, Bradham DM, Grotendorst GR. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell 1993; 4: 637-45.
81. Bradham DM, Igarashi A, Potter RL, Grotendorst GR. Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 1991; 114:1285-94.
82. Oemar BS, Luscher TF. Connective tissue growth factor. Friend or foe? Arterioscler Thromb Vasc Biol 1997; 17:1483-9.
83. Abraham D. Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc? Rheumatology (Oxford) 2008; 47 (Suppl 5): v8-9.
84. Fan WH, Pech M, Karnovsky MJ. Connective tissue growth factor (CTGF) stimulates vascular smooth muscle cell growth and migration in vitro. Eur J Cell Biol 2000; 79: 915-23.
85. Abreu JG, Ketpura NI, Reversade B, De Robertis EM. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 2002; 4: 599-604.
86. Nakanishi T, Nishida T, Shimo T, et al. Effects of CTGF/Hcs24, a product of a hypertrophic chondrocyte-specific gene, on the proliferation and differentiation of chondrocytes in culture. Endocrinology 2000; 141: 264-73.
87. Nishida T, Nakanishi T, Asano M, Shimo T, Takigawa M. Effects of CTGF/Hcs24, a hypertrophic chondrocyte-specific gene product, on the proliferation and differentiation of osteoblastic cells in vitro. J Cell Physiol 2000; 184:197-206.
88. Yamaai T, Nakanishi T, Asano M, et al. Gene expression of connective tissue growth factor (CTGF/CCN2) in calcifying tissues of normal and cbfa1-null mutant mice in late stage of embryonic development. J Bone Miner Metab 2005; 23: 280-8.
89. Ortlepp JR, Schmitz F, Mevissen V, et al. The amount of calciumdeficient hexagonal hydroxyapatite in aortic valves is influenced by gender and associated with genetic polymorphisms in patients with severe calcific aortic stenosis. Eur Heart J 2004; 25:514-22.
90. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 2004; 15:1983-92.
91. Haynes WG, Noon JP, Walker BR, Webb DJ. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens 1993; 11:1375-80.
92. Wilkinson IB, Hall IR, MacCallum H, et al. Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function. Arterioscler Thromb Vasc Biol 2002; 22:147-52.
93. Sudhir K, Mullen WL, Hausmann D, et al. Contribution of endothelium-derived nitric oxide to coronary arterial distensibility: an in vivo two-dimensional intravascular ultrasound study. Am Heart J 1995; 129: 726-32.
94. Fitch RM, Vergona R, Sullivan ME, Wang YX. Nitric oxide synthase inhibition increases aortic stiffness measured by pulse wave velocity in rats. Cardiovasc Res 2001; 51: 351-8.
95. Kinlay S, Creager MA, Fukumoto M, et al. Endothelium-derived nitric oxide regulates arterial elasticity in human arteries in vivo. Hypertension 2001; 38:1049-53.
96. Stewart AD, Millasseau SC, Kearney MT, Ritter JM, Chowienczyk PJ. Effects of inhibition of basal nitric oxide synthesis on carotidfemoral pulse wave velocity and augmentation index in humans. Hypertension 2003; 42: 915-8.
97. Wilkinson IB, MacCallum H, Cockcroft JR, Webb DJ. Inhibition of basal nitric oxide synthesis increases aortic augmentation index and pulse wave velocity in vivo. Br J Clin Pharmacol 2002; 53:189-92.
98. Bank AJ, Kaiser DR, Rajala S, Cheng A. In vivo human brachial artery elastic mechanics: effects of smooth muscle relaxation. Circulation 1999; 100: 41-7.
99. Dupuis M, Soubrier F, Brocheriou I, et al. Profiling of aortic smooth muscle cell gene expression in response to chronic inhibition of nitric oxide synthase in rats. Circulation 2004; 110: 867-73.
100. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J 1993; 7:1475-82.
101. Hunter GK, Goldberg HA. Nucleation of hydroxyapatite by bone sialoprotein. Proc Natl Acad Sci USA 1993; 90: 8562-5.
102. Tomita H, Egashira K, Ohara Y, et al. Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 1998; 32: 273-9.
103. Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, Chatziantoniou C. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 2003; 14:1132-44.
104. Kanno Y, Into T, Lowenstein CJ, Matsushita K. Nitric oxide regulates vascular calcification by interfering with TGF- signalling. Cardiovasc Res 2008; 77: 221-30.
105. Dao HH, Essalihi R, Graillon JF, Lariviere R, De Champlain J, Moreau P. Pharmacological prevention and regression of arterial remodeling in a rat model of isolated systolic hypertension. J Hypertens 2002; 20:1597-606.
106. Essalihi R, Dao HH, Gilbert LA, et al. Regression of medial elastocalcinosis in rat aorta: a new vascular function for carbonic anhydrase. Circulation 2005; 112:1628-35.
107. Park JB, Schiffrin EL. Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. Am J Hypertens 2002; 15:164-9.
108. Fakhouri F, Placier S, Ardaillou R, Dussaule JC, Chatziantoniou C. Angiotensin II activates collagen type I gene in the renal cortex and aorta of transgenic mice through interaction with endothelin and TGF-beta. J Am Soc Nephrol 2001; 12: 2701-10.
109. Boffa JJ, Tharaux PL, Dussaule JC, Chatziantoniou C. Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 2001; 37: 490-6.
110. Gonzalez W, Chen Z, Damon DH. Transforming growth factorbeta regulation of endothelin expression in rat vascular cell and organ cultures. J Cardiovasc Pharmacol 2001; 37: 219-26.
111. Rodriguez-Pascual F, Redondo-Horcajo M, Lamas S. Functional cooperation between Smad proteins and activator protein-1 regulates transforming growth factor-beta-mediated induction of endothelin-1 expression. Circ Res 2003; 92:1288-95.
112. Rodriguez-Vita J, Ruiz-Ortega M, Ruperez M, et al. Endothelin-1, via ETA receptor and independently of transforming growth factorbeta, increases the connective tissue growth factor in vascular smooth muscle cells. Circ Res 2005; 97:125-34.
113. Safar ME, Lajemi M, Rudnichi A, Asmar R, Benetos A. Angiotensin- converting enzyme D/I gene polymorphism and age-related changes in pulse pressure in subjects with hypertension. Arterioscler Thromb Vasc Biol 2004; 24: 782-6.
114. Lajemi M, Labat C, Gautier S, et al. Angiotensin II type 1 receptor-153A/G and 1166A/C gene polymorphisms and increase in aortic stiffness with age in hypertensive subjects. J Hypertens 2001; 19: 407-13.
115. Volpe M. Treatment of systolic hypertension: spotlight on recent studies with angiotensin II antagonists. J Hum Hypertens 2005; 19: 93-102.
116. Jimenez E, Perez de la Blanca E, Urso L, Gonzalez I, Salas J, Montiel M. Angiotensin II induces MMP 2 activity via FAK/JNK pathway in human endothelial cells. Biochem Biophys Res Commun 2009; 380: 769-74.
117. Tanaka H, Takai S, Jin D, et al. Inhibition of matrix metalloproteinase-9 activity by trandolapril after middle cerebral artery occlusion in rats. Hypertens Res 2007; 30: 469-75.
118. Ahimastos AA, Natoli AK, Lawler A, Blombery PA, Kingwell BA. Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertension 2005; 45:1194-9.
119. Tziakas DN, Chalikias GK, Stakos DA, et al. Effect of angiotensinconverting enzyme insertion/deletion genotype on collagen type I synthesis and degradation in patients with atrial fibrillation and arterial hypertension. Expert Opin Pharmacother 2007; 8: 2225-34.
120. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000; 52: 639-72.
121. Tunon J, Ruiz-Ortega M, Egido J. Regulation of matrix proteins and impact on vascular structure. Curr Hypertens Rep 2000; 2:106-13.
122. Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, Ruperez M, Egido J, Ruiz-Ortega M. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 2005; 111: 2509-17.
123. Ruperez M, Lorenzo O, Blanco-Colio LM, Esteban V, Egido J, Ruiz-Ortega M. Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation 2003; 108: 1499-505.
124. de las Heras N, Ruiz-Ortega M, Ruperez M, et al. Role of connective tissue growth factor in vascular and renal damage associated with hypertension in rats. Interactions with angiotensin II. J Renin Angiotensin Aldosterone Syst 2006; 7: 192-200.
125. Linseman DA, Benjamin CW, Jones DA. Convergence of angiotensin II and platelet-derived growth factor receptor signaling cascades in vascular smooth muscle cells. J Biol Chem 1995; 270:12563-8.
126. Kim S, Zhan Y, Izumi Y, Yasumoto H, Yano M, Iwao H. In vivo activation of rat aortic platelet-derived growth factor and epidermal growth factor receptors by angiotensin II and hypertension. Arterioscler Thromb Vasc Biol 2000; 20: 2539-45.
127. Nishioka T, Suzuki M, Onishi K, et al. Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosteronemediated inflammation. J Cardiovasc Pharmacol 2007; 49: 261-8.
128. Oei HH, Sayed-Tabatabaei FA, Hofman A, Oudkerk M, van Duijn CM, Witteman JC. The association between angiotensin-converting enzyme gene polymorphism and coronary calcification. The Rotterdam Coronary Calcification Study. Atherosclerosis 2005; 182:169-73.
129. Lalaoui MZ, El Midaoui A, de Champlain J, Moreau P. Is there a role for reactive oxygen species in arterial medial elastocalcinosis? Vascul Pharmacol 2007; 46: 201-6.
130. Izzo JL, Jr., Shykoff BE. Arterial stiffness: clinical relevance, measurement, and treatment. Rev Cardiovasc Med 2001; 2: 29-34, 37-40.
131. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865-72.
132. Honda T, Hamada M, Shigematsu Y, Matsumoto Y, Matsuoka H, Hiwada K. Effect of antihypertensive therapy on aortic distensibility in patients with essential hypertension: comparison with trichlormethiazide, nicardipine and alacepril. Cardiovasc Drugs Ther 1999; 13: 339-46.
133. Essalihi R, Zandvliet ML, Moreau S, et al. Distinct effects of amlodipine treatment on vascular elastocalcinosis and stiffness in a rat model of isolated systolic hypertension. J Hypertens 2007; 25:1879-86.
134. Rajzer M, Klocek M, Kawecka-Jaszcz K. Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension. Am J Hypertens 2003; 16: 439-44.
135. Hope SA, Hughes AD. Drug effects on the mechanical properties of large arteries in humans. Clin Exp Pharmacol Physiol 2007; 34: 688-93.
136. Albaladejo P, Bouaziz H, Duriez M, et al. Angiotensin converting enzyme inhibition prevents the increase in aortic collagen in rats. Hypertension 1994; 23: 74-82.
137. Lacolley P, Safar ME, Lucet B, Ledudal K, Labat C, Benetos A. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 2001; 37: 662-7.
138. Lopez B, Querejeta R, Varo N, et al. Usefulness of serum carboxyterminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001; 104: 286-91.
139. Suzuki H, Kanno Y, Kaneko K, et al. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy. Ther Apher Dial 2004; 8: 320-7.
140. Duchier J, Iannascoli F, Safar M. Antihypertensive effect of sustained-release isosorbide dinitrate for isolated systolic systemic hypertension in the elderly. Am J Cardiol 1987; 60: 99-102.
141. Stokes GS, Ryan M, Brnabic A, Nyberg G. A controlled study of the effects of isosorbide mononitrate on arterial blood pressure and pulse wave form in systolic hypertension. J Hypertens 1999; 17: 1767-73.
142. Cockcroft JR. Exploring vascular benefits of endothelium-derived nitric oxide. Am J Hypertens 2005; 18:177S-183S.
143. Fung HL, Poliszczuk R. Nitrosothiol and nitrate tolerance. Z Kardiol 1986; 75 (Suppl 3): 25-7.
144. Starmans-Kool MJ, Kleinjans HA, Lustermans FA, Kragten JA, Breed JG, Van Bortel LM. Treatment of elderly patients with isolated systolic hypertension with isosorbide dinitrate in an asymmetric dosing schedule. J Hum Hypertens 1998; 12:557-61.
145. Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001; 21: 817-24.
146. Ariyoshi T, Eishi K, Sakamoto I, Matsukuma S, Odate T. Effect of etidronic acid on arterial calcification in dialysis patients. Clin Drug Investig 2006; 26: 215-22.